Multiple sclerosis is a lifelong, immune-mediated progressive disorder. The early age of onset and the chronic nature of the disease with accumulation of physical disability, demand a long-term ("lifelong") management, including disease-modifying   more »

Botulinum toxin type A injections can decrease spasticity and improve quality of life in multiple sclerosis (MS) patients with spastic foot drop, according to   more »

Pluristem Therapeutics Inc. (NASDAQ:PSTI) (DAX:PJT) a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) [1] cell therapy products for a variety of degenerative, ischemic and autoimmune indications, announced today that a preclinical study utilizing the   more »

The investigational oral therapy FTY720 (fingolimod) continues to demonstrate sustained benefits in patients with multiple sclerosis (MS) after three years of treatment, according to new   more »

Genentech, Inc. (NYSE: DNA) and Biogen Idec, Inc. (Nasdaq: BIIB) today announced that a Phase II/III study of Rituxan® (rituximab) for primary-progressive multiple sclerosis (PPMS) did not meet its primary endpoint as measured by the time to   more »

MediciNova reports encouraging results from Phase II multiple sclerosis trial

 

 

MediciNova has announced positive clinical findings from the completed two-year Phase II clinical trial of orally administered MN-166 for the treatment of multiple sclerosis.

 

The data showed that sustained disability progression was significantly less likely (by approximately 50%) in those patients receiving MN-166 at either 30 or 60mg per day for 24 months than in those patients receiving the drug for 12 months (p=0.026).

 

The clinical trial demonstrated that the significant reduction in brain volume loss (p=0.035), as measured by cranial magnetic resonance imaging (MRI) scans, observed after 12 months in patients treated with 60mg per day of MN-166 compared to placebo were again demonstrated in year two of the study. Brain volume loss was significantly less (p=0.030) in patients receiving 60mg per day of MN-166 for 24 months compared to the other treatment groups.

 

The data also showed that MN-166 treatment at 60mg per day significantly reduced the relative risk for conversion of new inflammatory lesions identified at month two to Persistent Black Holes (PBH), an MRI indicator of neuronal loss, eight months later at month ten by 37% (p=0.011); such lesions that remain unchanged for eight months are considered PBHs as compared to transient inflammatory lesions that are more closely associated with relapses. MN-166 treatment at 30mg per day resulted in a trend toward reducing evolution to PBH (p=0.074). Loss of brain volume and development of PBHs on MRI have been shown to correlate with clinical progression and disability in MS patients. 

 

MBP8298 is a synthetic peptide that consists of 17 amino acids linked in a sequence identical to that of a portion of human myelin basic myelin basic protein (MBP). MBP8298 has been developed for the treatment of multiple sclerosis (MS), and is based on over 26 years of research   more »